AbCellera Biologics vs Recursion Pharmaceuticals
AbCellera Biologics reported revenue of $75 million in fiscal 2025, about the same as Recursion Pharmaceuticals' $75 million in fiscal 2025. AbCellera Biologics' revenue grew 160.6% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. AbCellera Biologics had an operating margin of -289.0%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was −$174 million at AbCellera Biologics and −$378 million at Recursion Pharmaceuticals.
Side by side
| AbCellera Biologics | Recursion Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $75M | $75M |
| Revenue growth | 160.6% | 26.9% |
| Revenue growth a year, last 5 years | −20.3% | 79.6% |
| Gross margin | — | 5.0% |
| Operating margin | −289.0% | −867.9% |
| Net margin | −194.9% | −863.4% |
| Free cash flow | −$174M | −$378M |
| Free cash flow margin | −231.7% | −506.5% |
| Return on capital | — | −117.2% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.5% | 63.2% |
| Last close | $10.47 | $2.72 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $2.7 million, sold $0 | sold $6.9 million |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbCellera BiologicsRecursion Pharmaceuticals
Operating margin
Percent of revenue
AbCellera BiologicsRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbCellera BiologicsRecursion Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbCellera Biologics and Recursion Pharmaceuticals pages.